Passamonti F - Search Results

1

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A. Passamonti F, et al. Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26. Blood. 2012. PMID: 22740446 Free article.

2

Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.

Passamonti F, Malabarba L, Orlandi E, Pascutto C, Brusamolino E, Astori C, Baratè C, Canevari A, Corso A, Bernasconi P, Cazzola M, Lazzarino M. Passamonti F, et al. Br J Haematol. 2002 Mar;116(4):855-61. doi: 10.1046/j.0007-1048.2002.03367.x. Br J Haematol. 2002. PMID: 11886392 Free article.

3

Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.

Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M. Passamonti F, et al. Haematologica. 2003 Jan;88(1):13-8. Haematologica. 2003. PMID: 12551821

4

Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.

Passamonti F, Vanelli L, Malabarba L, Rumi E, Pungolino E, Malcovati L, Pascutto C, Morra E, Lazzarino M, Cazzola M. Passamonti F, et al. Haematologica. 2003 Oct;88(10):1123-9. Haematologica. 2003. PMID: 14555308

5

Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.

Arcaini L, Paulli M, Boveri E, Vallisa D, Bernuzzi P, Orlandi E, Incardona P, Brusamolino E, Passamonti F, Burcheri S, Schena C, Pascutto C, Cavanna L, Magrini U, Lazzarino M. Arcaini L, et al. Among authors: passamonti f. Cancer. 2004 Jan 1;100(1):107-15. doi: 10.1002/cncr.11893. Cancer. 2004. PMID: 14692030 Free article.

6

Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.

Passamonti F, Rumi E, Malabarba L, Arcaini L, Orlandi E, Brusamolino E, Pascutto C, Cazzola M, Lazzarino M. Passamonti F, et al. Ann Hematol. 2004 Aug;83(8):495-7. doi: 10.1007/s00277-004-0882-7. Epub 2004 Jun 3. Ann Hematol. 2004. PMID: 15175894 No abstract available.

7

Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders.

Passamonti F, Pietra D, Malabarba L, Rumi E, Della Porta MG, Malcovati L, Bonfichi M, Pascutto C, Lazzarino M, Cazzola M. Passamonti F, et al. Br J Haematol. 2004 Sep;126(5):650-6. doi: 10.1111/j.1365-2141.2004.05098.x. Br J Haematol. 2004. PMID: 15327515 Free article.

8

Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.

Passamonti F, Cazzola M. Passamonti F, et al. Haematologica. 2004 Nov;89(11):1284. Haematologica. 2004. PMID: 15531447 No abstract available.

9

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Passamonti F, et al. Am J Med. 2004 Nov 15;117(10):755-61. doi: 10.1016/j.amjmed.2004.06.032. Am J Med. 2004. PMID: 15541325

10

PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia.

Passamonti F, Pietra D, Rumi E, Arcaini L, Della Porta MG, Malcovati L, Pascutto C, Lazzarino M, Cazzola M. Passamonti F, et al. Leukemia. 2005 May;19(5):888-9. doi: 10.1038/sj.leu.2403700. Leukemia. 2005. PMID: 15744342 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

433 results

Search Page

Filters